Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Coronary Artery DiseaseDiabetes Mellitus Type 2
Interventions
DRUG

Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

University of Nebraska

OTHER

collaborator

Astellas Pharma US, Inc.

INDUSTRY

collaborator

Lantheus Medical Imaging

INDUSTRY

lead

Mayo Clinic

OTHER